重用FDA批准的药物以针对MTH1进行抗癌疗法
Aaliya Taiyab1, Md Nayab Sulaimani1, Aanchal Rathi2
1Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India.
Journal of molecular recognition : JMR
|June 22, 2025
概括
研究人员选了FDA批准的药物,并确定了Lumacaftor和Nilotinib作为MTH1 (MutT Homolog-1) 的潜在抑制剂. 尼罗丁尼通过向MTH1来治疗癌症,显示出对癌症治疗的希望,为抗药性提供了一种新的策略.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 计算生物学 计算生物学
背景情况:
- 癌细胞具有高反应性氧物种,导致氧化应激和DNA损伤.
- 在癌症中,MTH1 (MutT Homolog-1) 酶被上调,以排毒氧化核酸.
- 抑制MTH1是一种诱导癌细胞死亡的治疗策略.
研究的目的:
- 以计算方式选FDA批准的药物用于MTH1抑制剂.
- 确定用于癌症治疗的新型MTH1抑制剂.
- 探索药物重用,以克服癌症化学抵抗.
主要方法:
- 对3800种FDA批准的药物的计算选.
- 分子动力学模拟 (500 ns) 以评估药物-MTH1结合的稳定性.
- 结合亲和力 (Ka) 和抑制活性 (IC50) 的评估.
主要成果:
- 卢马卡夫托和尼罗丁尼被确定为潜在的MTH1抑制剂.
- 尼罗丁尼表现出强大的结合亲和力 (Ka = 2.5 × 10^4) 和强大的MTH1抑制 (IC50 = 37.2 μM).
- 这项研究是首次报告尼洛尼和MTH1.1之间的相互作用.
结论:
- 尼罗丁尼表现出双重潜力,作为氨酸激酶抑制剂和MTH1抑制剂.
- 针对MTH1抑制而重新利用尼洛丁尼,为对抗癌症抗药性提供了一种新的方法.
- 这一战略为改善癌症治疗结果开辟了新的治疗途径.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
Electron Transport Chain: Complex I and II
15.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.1K


